# Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults

> **NCT00192465** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 30 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **BIOLOGICAL:** MEDI-524 (Numax-TM)
- **BIOLOGICAL:** MEDI-524 (Numax-TM)
- **BIOLOGICAL:** MEDI-524 (Numax-TM)
- **BIOLOGICAL:** MEDI-524 (Numax-TM)
- **BIOLOGICAL:** MEDI-524 (Numax-TM)

## Key facts

- **NCT ID:** NCT00192465
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2004-04
- **Final completion:** 2004-11
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2009-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00192465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00192465, "Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00192465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*